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Background/aim: Intralesional recombinant epidermal growth factor (EGF) is a new treatment approach for diabetic foot ulcer,
approved in 2006. EGF therapy is given as an adjunct to the standard treatment regimen of antibiotics, surgery, and hyperbaric oxygen.
EGF accelerates the healing of diabetic foot ulcers and reduces healing time. This single-center study was conducted to evaluate the
outcomes of intralesional EGF therapy in patients with diabetic foot ulcers.
Materials and methods: We present the data of the follow-up patients treated in our clinics. Fifteen patients with diabetic foot ulcers or
infections, who had been followed up and treated in our clinics, were included in this retrospective study. All patients were administered
intralesional injections of 75 µg of EGF after treatment for infection on their diabetic foot ulcers, three times a week on alternate days.
The patients were monitored with respect to treatment response and side effects of EGF.
Results: Thirteen patients (86.7%) developed new granulation tissue, 10 patients (66.7%) had complete wound closure, and three
patients (20%) showed partial wound closure. No serious side effects requiring discontinuation of EGF therapy were observed. A total
of twenty-one bacterial agents were isolated in thirteen patients, and no bacterial growth was observed in the tissue cultures of two
patients. Pseudomonas aeruginosa was the most common isolated infectious agent in the tissue cultures (n: 6, 28%).
Conclusion: Intralesional injection of EGF on top of the standard treatment regimen appears to be a useful adjuvant therapy option in
selected patients.
Key words: Diabetic foot, intralesional epidermal growth factor, wound healing

1. Introduction
The prevalence of diabetes mellitus and diabetes-related
complications is continuously increasing. Diabetic foot
ulcers represent one of the most common complications
of diabetes and negatively affect patients’ quality of life.
Current estimates indicate that 15% of the entire diabetic
patient population experiences diabetic foot ulcers at
some point in their lives (1). This generates a significant
burden in terms of healthcare costs. Diabetic foot ulcers
impair the patients’ quality of life, increase treatment costs
substantially, lead to lower extremity amputations, and
eventually increase mortality. The average duration of
hospital stay among diabetics with foot ulcers is at least
50% longer than that of diabetics without foot ulcers. In
the first 4 years after a lower limb amputation, amputation
* Correspondence: ilginyildirim@hotmail.com
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of the other leg becomes a matter of concern in more than
50% of patients. The relative risk of mortality has been
shown to increase by almost 2.5-fold in diabetics who
developed new foot ulcers.
The basic treatment approach to diabetic foot
ulcers is based on metabolic control, good wound care,
debridement, and appropriate antimicrobial therapy. New
treatment methods, such as graft closure and intralesional
injection of epidermal growth factor, have been developed
for lower-stage wounds and neuropathic ulcers. However,
alternative therapy options are still limited for higher-stage
wounds, and amputation may become inevitable in such
cases (2,3). Clinical trials have previously demonstrated
the beneficial effects of intralesional epidermal growth
factor (EGF) therapy in lower-stage neuropathic ulcers (4).

IŞIKGÖZ TAŞBAKAN et al. / Turk J Med Sci
This single-center study was conducted to evaluate the
outcomes of intralesional EGF therapy in patients with
diabetic foot ulcers.
2. Materials and methods
Fifteen patients, who had been followed up with diabetic
foot ulcers or infections, and had been given intralesional
EGF therapy after the treatment of infection in our clinics
between January 2014 and May 2016, were included in
this study. We present the data of follow-up patients in our
clinics. The patients were grouped by data records such as
age, sex, duration of diabetes, previous history of diabetic
foot, history of peripheral artery disease, history of
osteomyelitis, nephropathy, and localization of the ulcer.
All the data were recorded on patient follow-up forms.
Foot pathologies were assessed by trained physicians,
based on the criteria of the International Working Group
on the Diabetic Foot [PEDIS (Perfusion, Extent/size,
Depth/tissue loss, Infection, Sensation classification)].
Tissue samples were obtained from all patients at the time
of admission. In total, 6–8 intralesional EGF injections
at a dose of 75 µg/day were administered to the patients
three times a week on alternate days. Before each EGF
injection, necrotic and infected tissue at the injection
site was debrided by a physician. Intralesional EGF
therapy was initiated in all patients after the infection was
controlled through adequate surgical debridement and
antibiotherapy. EGF vials, supplied in cold chain, were
stored at +4 °C. EGF was dissolved in 5 mL of sterile water
and injected deep into the tissues surrounding the lesion.
According to the prespecified criteria, wound healing was
assessed by measuring the area of granulation tissue on
the lesion surface and calculating the ratio of the area of
granulation tissue to the total lesion area. A ratio of <25%
was considered to indicate lack of response, whereas the
ratios of 26%–50%, 51%–75%, and >76% were considered
to imply minimal response, partial response, and complete
response, respectively. Side effects were monitored
daily. All patients attended regular follow-up visits after
completion of EGF therapy.
3. Results
A total of 15 patients were included in the present study.
All patients had Type 2 diabetes mellitus and were
undergoing insulin therapy. Table 1 summarizes the
demographical and clinical data of the patient population.
Thirteen (86.7%) patients had a history of debridement or
minor amputation. Microbiological investigations were
performed for all patients. A total of 21 bacterial agents
were isolated in 13 of 15 cases, while no bacterial growth
occurred in the tissue samples obtained from two cases.
The most commonly isolated bacteria were Pseudomonas
aeruginosa (n: 6, 28%). The other infectious agents are
listed in Table 2.

Table 1. Demographic and clinical characteristics of patients.
Demographic and clinical characteristics

N (%)

Age (mean ± SD)
Sex (male)
Duration of diabetes (mean, years)
History of debridement
Duration of ulcers (days)
Previous history of diabetic foot
History of peripheral artery disease
History of osteomyelitis
Nephropathy
Baseline PEDIS
Mild
Moderate
Severe
Right foot wound
Left foot wound
Localization of the ulcer
Toes, distal foot
Foot sole
Heel
Dorsum, lateral foot
Ankle
Calf
Outcome
Complete response (granulation tissue >75%)
Partial response (granulation tissue 51%–75%)
No response

59.47 ± 9.3
11 (73)
17.67 ± 8.8
13 (86.7)
198.13 ± 227.9
7 (46.7)
8 (53.3)
8 (53.3)
7 (46.7)
4 (26.7)
10 (66.7)
1 (6.7)
6 (40)
11 (73.3)
7 (46.7)
8 (53.3)
3 (20)
5 (33.3)
1 (6.7)
4 (26.7)
10 (66.7)
3 (20)
2 (13.3)

Table 2. Bacteria isolated from diabetic foot infections.
Agent

N (%)

Gram positive cocci

6 (29%)

Staphylococcus aureus

4

Methicillin sensitive

3

Methicillin resistant

1

Streptococcus agalactiae

1

Enterococcus faecalis

1

Gram negative bacilli

15 (71%)

Pseudomonas aeruginosa

6

Proteus spp.

3

P. mirabilis

2

P. vulgaris

1

Enterobacter cloacae

2

Klebsiella pneumoniae

1

Stenotrophomonas maltophilia

1

Serratia marcescens

1

Citrobacter braakii

1

Total

21 (100%)
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Ten patients (66.6%) developed >75% and three (20%)
developed 51%–75% granulation tissue on the wound
surface. Two (13.3%) did not respond to intralesional EGF
therapy. Two patients, who experienced skin eruption,
pruritus, and temperature increase of the extremity
during the first injection, responded to symptomatic
therapy (paracetamol and antihistaminics). Subsequent
EGF injections were uneventful after administration
of premedications. No serious side effects requiring
discontinuation of EGF therapy were noted during the
follow-up period. Two of the patients with complete
response are shown in the Figure.
4. Discussion
Prevention and treatment of diabetic foot ulcers can
be very challenging, as there are several factors that
significantly contribute to their development, and each of
these factors should be addressed separately. The ultimate
goal of treatment of diabetic foot ulcers is to achieve
complete wound closure whenever possible. While the
basic treatment
approaches
are based
oninjection
tight metabolic
Case
1: Intralesional
EGF
control, good wound care, debridement, and appropriate
Before EGF

antimicrobial therapy, there is still a medical need for
novel therapies (5). In this context, intralesional EGF
therapy stands out as one of the complementary therapy
options that may provide some benefit to selected patients.
Growth factors are proteins that regulate intracellular
and intercellular signals. These proteins regulate controlled
cell growth, proliferation, and differentiation; thus, they
ensure that the skin maintains a healthy structure to
function normally. EGF plays a mitogenic role in wound
healing and induces migration of the cells responsible for
wound closure to the site of ulceration, formation of the
granulation tissue, angiogenesis, contraction of the wound
borders by myofibroblasts, proliferation of epithelial
cells, and their migration to the site of ulceration (6).
Chronic wounds are characterized by decreased growth
factor expression in wound tissue. Several studies have
demonstrated that it is possible to accelerate wound
healing by therapeutic use of growth factors.
In a study by Acosta et al. (2006), three-times-weekly
EGF therapy at a dose of 25 µg/day was administered for 8
weeks to 29 patients at high risk (Wagner 3–4) of amputation
with ischemic and/or neuropathic components. After the
After EGF (Injection 8)

Case 1: Intralesional EGF injection
Before EGF

After EGF (Injection 8)

Case 2: Intralesional EGF injection
Before EGF

After EGF (Injection 8)

Figure. Descriptive case images before and after intralesional EGF injection.
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eighth injection, 86% of the patients developed granulation
tissue and re-epithelialization was achieved on the day 66
on average in 77% of the patients. The authors reported
that a potential amputation was prevented in 17 (58%)
patients, and underlined the efficacy of intralesional EGF
therapy in decreasing amputation rates (7).
In their 2007 study comparing intralesional EGF doses
of 75 µg (n: 23) and 25 µg (n: 18), Fernandez-Montequin
et al. reported faster and more frequent formation of
granulation tissue under a higher dose of EGF therapy
(83% and 61%, respectively) (8).
In a multicentral Turkish study published in 2015,
Ertugrul et al. assessed the efficacy of intralesional EGF
therapy in 17 patients with diabetic foot ulcers. All
patients were given three-times-weekly intralesional EGF
at a dose of 75 µg. Wound closure was achieved in three
patients (18%), whereas 13 patients (76%) developed
>75% granulation tissue (9).
In the present study, 10 patients (66.7%) had moderate
diabetic foot ulcers, 4 (26.6%) had mild, and one (6.7%)
had severe, based on the PEDIS classification. Ten patients
(66.7%) developed >75% granulation tissue on the wound
surface, whereas three patients (20%) developed 51%–75%
granulation tissue. Two patients (13.3%) did not respond
to intralesional EGF therapy. One of the unresponsive
patients had severe ulcers and the other had moderate
ones, based on the PEDIS classification.
Diabetic foot infections are usually polymicrobial (10).
Causative agents may include gram positive cocci, gram
negative bacilli, and anaerobes. In the study by Ertugrul et
al., no bacterial growth was observed in the tissue cultures
of two of 17 patients given intralesional EGF therapy, and
a total number of 21 bacteria species were isolated from
the tissue cultures of the remaining 15 patients. In that
study, the most frequently isolated bacteria specie was
Pseudomonas aeruginosa (n = 7, 33%). Moreover, the most
commonly reported side effects in their patients were
tremor (n = 10, 59%) and nausea (n = 6, 35%). EGF therapy
was discontinued in one patient due to a serious side
effect (9). Microbiological investigations were performed

in all cases in the present study, and the most frequently
isolated species was Pseudomonas aeruginosa. In terms
of side effects, two patients experienced skin eruption,
pruritus, and temperature increase of the extremity during
the first injection, and then responded to symptomatic
therapy (paracetamol and antihistaminics). Subsequent
EGF injections were uneventful after administration of
premedications, and no serious side effects requiring
discontinuation of EGF therapy were noted.
Although intralesional EGF may be a good
complementary treatment option in appropriate cases, it
continues to be an expensive therapy. In Turkey, a single
vial costs 2210.98 TL (as of 5 April 2016) and the total
treatment cost (three-times-weekly for 8 weeks) can
amount to approximately 53,000 TL ($17,700). In a recent
study by Eggert (2016), the total healthcare expenditure of
a patient with lower extremity amputation due to diabetic
foot infection was reported to range between $66,300 and
$73,000 (11). Although intralesional EGF therapy appears
to be an expensive option, it can still be cost-effective
compared to the lower extremity amputations performed
due to diabetic foot infections. Preserving the extremity
is the most important advantage of this complementary
treatment modality for appropriate patients.
In conclusion, the number of patients with diabetic
foot ulcers continues to increase, and unfortunately these
ulcers can result in major amputations. Intralesional
EGF is a promising treatment option for preventing
progression of diabetic foot ulcers and decreasing the rate
of amputations among appropriate patients with diabetic
foot ulcers. Previous studies and currently available
data indicate that intralesional EGF can be an effective
complementary treatment option in selected patients with
diabetic foot ulcers.
To the best of our knowledge, this study involves the
largest patient series reported so far from a single center
in Turkey. Nevertheless, additional studies and long-term
follow-up data are required to obtain more detailed clinical
information on intralesional EGF therapy.

References
1.

Muhtaroğlu S, Barlak D, Ünlühizarcı K. Investigation of
ischemia-modified albumin levels and some atherosclerosisrelated serum parameters in patients with diabetic foot. Turk J
Med Sci 2016; 46: 126-132.

2.

Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical
gel formulation of recombinant human platelet-derived growth
factor-BB (becaplermin) in patients with chronic neuropathic
diabetic ulcers. A phase III randomized placebo-controlled
double-blind study. Diabetes Care 1998; 21: 822-827.

3.

Veves A, Falanga V, Armstrong DG, Sabolinski ML. Graftskin,
a human skin equivalent, is effective in the management of
noninfected neuropathic diabetic foot ulcers: a prospective
randomized multicenter clinical trial. Diabetes Care 2001; 24:
290-295.

4.

Hong JP, Jung HD, Kim YW. Recombinant human epidermal
growth factor (EGF) to enhance healing for diabetic foot ulcers.
Ann Plast Surg 2006; 56: 394-398.

1503

IŞIKGÖZ TAŞBAKAN et al. / Turk J Med Sci
5.

Rubio JA, Aragón-Sánchez J, Jiménez S, Guadalix G, Albarracín
A, Salido C, Sanz-Moreno J, Ruiz-Grande F, Gil-Fournier N,
Álvarez J. Reducing major lower extremity amputations after
the introduction of a multidisciplinary team for the diabetic
foot. Int J Low Extr Wound 2014; 13: 22-26.

6.

Berlanga-Acosta J. Diabetic lower extremity wounds: the
rationale for growth factors-based infiltration treatment. Int
Wound J 2011; 8: 612-620.

7.

Acosta JB, Savigne W, Valdez C, Franco N, Alba JS, del Rio A,
López-Saura P, Guillén G, Lopez E, Herrera L et al. Epidermal
growth factor intralesional infiltrations can prevent amputation
in patients with advanced diabetic foot wounds. Int Wound J
2006; 3: 232-239.

8.

Fernandez-Montequin JI, Infante-Cristia E, Valenzuela-Silva
C, Franco-Pérez N, Savigne-Gutierrez W, Artaza-Sanz H,
Morejón-Vega L, González-Benavides C, Eliseo-Musenden O,
García-Iglesias E et al. Intralesional injections of Citoprot-P
(recombinant human epidermal growth factor) in advanced
diabetic foot ulcers with risk of amputation. Int Wound J 2007;
4: 333-43.

1504

9.

Ertugrul BM, Buke C, Ersoy OS, Ay B, Demirez DS, Savk O.
Intralesional epidermal growth factor for diabetic foot wounds:
the first cases in Turkey. Diabet Foot Ankle 2015; 6: 28419.

10. Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS,
Karchmer AW, LeFrock JL, Lew DP, Mader JT, Norden C et al.
Diagnosis and treatment of diabetic foot infections. Clin Infect
Dis 2004; 39: 885-910.
11. Eggert JV, Worth ER, Van Gils CC. Cost and mortality data of
a regional limb salvage and hyperbaric medicine program for
Wagner Grade 3 or 4 diabetic foot ulcers. Undersea Hyperb
Med 2016; 43: 1-8.

